The purpose of this study is to investigate the effect of orally inhaled AP-301 on primary graft dysfunction after lung transplantation.

Inclusion Criteria:

• Being a male or female recipient on the AKH's waiting list for primary single or double LuTX
• PGD score ≥ 1 within 72 hours after LuTX
• Informed consent is available

Exclusion Criteria:

• History of clinically relevant allergies or idiosyncrasies to AP301 or any other inactive ingredient(s) of the investigational product
• Postoperative ECMO support
• Paediatric /adolescent recipients (< 18 years)
• Lobar transplantation
• Retransplantation
• Combined solid organ transplants
• Participation in other drug trials